Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 89.15M | $ 30.00K | $ 1.32M | $ 5.51M | $ 17.84M |
| Gross Profit | $ 68.59M | $ 30.00K | $ 1.32M | $ 5.29M | $ 3.77M |
| Operating Income | $ -3.08M | $ -67.52M | $ -35.52M | $ -19.45M | $ -469.00K |
| EBITDA | $ -3.00M | $ -67.45M | $ -35.20M | $ -19.24M | $ -463.00K |
| Net Income | $ 8.00M | $ -54.37M | $ -34.68M | $ -20.24M | $ -1.06M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 314.02M | $ 228.36M | $ 274.38M | $ 60.06M | $ 24.52M |
| Total Assets | $ 351.15M | $ 233.19M | $ 281.44M | $ 61.45M | $ 26.41M |
| Total Debt | $ 42.00K | $ 274.00K | $ 481.00K | $ 9.03M | $ 10.02M |
| Net Debt | $ -50.77M | $ -70.70M | $ -210.04M | $ -51.03M | $ -14.50M |
| Total Liabilities | $ 94.36M | $ 2.43M | $ 8.55M | $ 92.72M | $ 40.46M |
| Stockholders' Equity | $ 256.80M | $ 230.76M | $ 272.89M | $ -31.27M | $ -14.05M |
| Cash Flow | |||||
| Free Cash Flow | $ 12.98M | $ -59.44M | $ -40.28M | $ -17.62M | $ 8.15M |
| Operating Cash Flow | $ 13.55M | $ -59.27M | $ -40.08M | $ -17.56M | $ 9.07M |
| Investing Cash Flow | $ -106.10M | $ -87.18M | $ -199.00K | $ -55.00K | $ -917.00K |
| Financing Cash Flow | $ 72.40M | $ 6.90M | $ 190.73M | $ 53.16M | $ 5.10M |